In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp

Aki Yoneda(Washington University in St. Louis), Gautam Dantas(Washington University in St. Louis), Carey‐Ann D. Burnham(Washington University in St. Louis), Robert Thänert(Washington University in St. Louis)
International Journal of Antimicrobial Agents
December 20, 2019
Cited by 10


Related Papers